Can trained immune cells stop blood cancer relapse?

NCT ID NCT02203903

Recruiting now Disease control Sponsor: Catherine Bollard Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether giving patients special immune cells, called TAA-T, after a stem cell transplant can help prevent high-risk blood cancers like acute myeloid leukemia from coming back. The cells are designed to recognize three common tumor markers and attack any remaining cancer cells. The study includes patients aged 6 months to 80 years with high-risk AML or MDS who are receiving or have received a transplant. The main goal is to see if the treatment is safe and to measure how long patients stay free of their cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor-associated antigen lymphocytes (TAA-T), a type of immune cell therapy designed to recognize and attack cancer cells expressing WT1, PRAME, and survivin.
What this could lead to: If successful, this approach could offer a new way to prevent relapse after stem cell transplant for high-risk blood cancers, potentially improving long-term survival.
What could go wrong: This is an early-phase trial, so safety and effectiveness are not yet proven. Risks include graft-versus-host disease, infusion reactions, and the possibility that the cells may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid system neoplasm myelodysplastic syndrome Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY HEMATOPOIETIC MALIGNANCIES, ACUTE MYELOID LEUKEMIA AND MDS

Contacts and locations

Locations

Childrens National Medical Center
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Tania Jain, MD
RECRUITING

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.